Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) on November 8 and set a price target ...

In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report). The ...

Prior to Rectify, she was Chief Financial Officer at Akouos, Inc., where she led corporate finance ... compared to amounts ...

James Investment Research Inc. purchased a new stake in Alkermes ... Hedge funds and other institutional investors own 95.21% of the company’s stock. Alkermes plc, a biopharmaceutical company ...

(RTTNews) - Alkermes plc (ALKS) released a profit for its third quarter that increased from last year but missed the Street estimates. The company's ... those of Nasdaq, Inc. Founded in the ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Alkermes plc announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small ... Most recently, she served as Vice President of CNS biology at Alkermes, Inc., where she led preclinical biology ...